Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter HAEMONETICS CORP updates investors on blood management business. Operational focus supports long-term growth outlook
Haemonetics Corp, a medical technology company specializing in blood management systems, continues to update investors on its operational focus. The company invests in core platforms and software tools to support hospitals and blood centers globally, aiming to improve patient care and control costs. Its strategy emphasizes deep integration into clinical workflows and maintaining long-standing relationships with healthcare providers.
Enterprise value to EBIT forward of Haemonetics Corporation – SWB:HAZ
This article provides financial information for Haemonetics Corporation (SWB:HAZ), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded and presents a navigation link to financial data on TradingView.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Corporation (HAE) is poised for growth driven by its Plasma franchise and the NexSys PCS system. Despite strong performance in its Plasma business and the potential of new technology, concerns remain regarding its debt-burdened balance sheet and competitive market. The article suggests that while Haemonetics has upsides, its financial leverage and competitive landscape warrant caution.
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers
Haemonetics Corp is adjusting its plasma collection strategy and focusing on growth in its key business lines, particularly automated plasmapheresis platforms and blood management systems for hospitals. The company provides equipment and software for plasma centers rather than owning them, leading to more stable revenue streams. Their shares, traded on the NYSE, are being compared with other U.S. medtech companies as they emphasize device innovation and digital integration.
Haemonetics Corporation(NYSE: HAE) added to Russell 2500 Value Benchmark
Haemonetics Corporation (NYSE: HAE), a medical technology company specializing in blood and plasma technologies, has been added to the Russell 2500 Value Benchmark. This inclusion is part of several recent additions to various Russell indices, reflecting increased recognition and market value for the company. Haemonetics' stock closed down 2.81% on June 29th, with an average analyst target price suggesting a potential upside of over 13%.
Haemonetics Corporation(NYSE: HAE) added to Russell 2000 Value Benchmark
Haemonetics Corporation (NYSE: HAE), a medical technology company, has been added to the Russell 2000 Value Benchmark. This update reflects the company's position within the small-cap value segment of the market. The article also provides recent news and financial data for Haemonetics, including its stock performance and analyst consensus.
Haemonetics Corporation(NYSE: HAE) added to Russell 2000 Value-Defensive Index
Haemonetics Corporation (NYSE: HAE) has been added to the Russell 2000 Value-Defensive Index. This medical technology company specializes in solutions for critical medical needs, including hospital technologies, plasma collection, and blood center products. The addition to the index highlights its market recognition and financial standing.
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE)
Haemonetics Corporation (HAE) has been included in several Russell value and defensive indexes, which is expected to increase passive ownership and liquidity, reinforcing its position as a value-tilted medtech stock. While this inclusion will impact trading dynamics, the core investment narrative still hinges on the company's ability to grow earnings from its focused medtech portfolio, manage U.S. market concentration and product dependence, and address elevated debt. Investors will be closely watching the impact of the FDA labeling expansion for VASCADE MVP XL on utilization and its potential to offset recent earnings and one-off losses.
Enterprise value to revenue forward of Haemonetics Corporation – NYSE:HAE
This article provides financial information for Haemonetics Corporation (NYSE: HAE), specifically detailing its enterprise value to revenue forward metric. The content, sourced from TradingView, focuses on the company's financials within the Health Technology sector.
Price to sales forward of Haemonetics Corporation – NYSE:HAE
This article from TradingView displays the "Price to sales forward" financial metric for Haemonetics Corporation (NYSE:HAE). The page appears to be a financial data presentation without explanatory text, showing only the period, value, and change for this specific metric. It is part of a larger financial overview for the company on the TradingView platform.
Enterprise value to revenue forward of Haemonetics Corporation – FWB:HAZ
This page provides financial data for Haemonetics Corporation (HAZ) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to revenue forward. It is a data-centric page without a narrative article.
Price to sales forward of Haemonetics Corporation – FWB:HAZ
This page from TradingView provides financial data for Haemonetics Corporation (FWB:HAZ), specifically its price to sales forward. It shows that the market is currently closed with no trades recorded for the stock. The content focuses purely on this financial metric without further analysis or commentary.
Price to earnings forward of Haemonetics Corporation – NYSE:HAE
This page provides financial information for Haemonetics Corporation (NYSE: HAE), specifically detailing its forward Price to Earnings (P/E) ratio. The content is primarily a financial data point from TradingView, indicating no current trades for the company and listing various financial and community features of the platform.
Price to earnings forward of Haemonetics Corporation – FWB:HAZ
This page from TradingView provides financial information for Haemonetics Corporation (FWB:HAZ), specifically focusing on its Price to Earnings (forward) metric. It lists the company on the Frankfurt Stock Exchange within the Health Technology and Medical Specialties sectors. The article indicates that the market is currently closed with no trades.
Enterprise value to EBITDA forward of Haemonetics Corporation – NYSE:HAE
This article presents financial information for Haemonetics Corporation (NYSE: HAE), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It highlights that this data point is accessible through the TradingView platform, which provides various financial tools and market data services. The content is primarily a data point embedded within a larger financial platform interface.
Haemonetics Corporation Actuals & Estimates (NYSE:HAE)
This article provides financial actuals and estimates for Haemonetics Corporation (NYSE: HAE), including details on its stock performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's recent stock price movements, upcoming earnings report date, and financial statistics like EBITDA and net income.
Enterprise value to EBITDA forward of Haemonetics Corporation – SWB:HAZ
This article provides financial data for Haemonetics Corporation (SWB:HAZ) on the Stuttgart Stock Exchange, specifically focusing on its Enterprise Value to EBITDA forward. The content appears to be a stub or a section within a larger financial platform, offering no specific values but frameworks for viewing financial metrics. The article is part of TradingView's market data offerings.
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100
Haemonetics Corp (HAE) saw its stock rise by 6.5% to $77.62 on June 25, 2026, and is considered 8.5% undervalued compared to its GF Value™ of $84.82. The company holds a strong GF Score™ of 84/100, driven by high profitability and growth ranks, despite a neutral stance from insiders with no recent transactions. Investors may find a potential opportunity given its undervaluation, although its current P/E is above its historical median.
HAE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Haemonetics Corporation (HAE) stock, including analyst price targets, current stock performance, and financial data. It covers historical prices, volatility, market capitalization, upcoming earnings reports, and revenue details, while also addressing frequently asked questions about investing in HAE.
Haemonetics Jumps 5.9% Amid Sector-Wide Rally
Haemonetics Corporation (HAE) saw its stock surge by 5.9% on Thursday, closing at $77.16 due to a broad sector-wide rally, not company-specific news. The strong performance, which included sector peers like QDEL and NEOG also making gains, suggests a general investor rotation into the medical devices sector. The article advises monitoring whether this sector momentum will be sustained by fundamental developments or prove to be a temporary market movement.
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Haemonetics Corp (HAE), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, HAE has a price momentum score of 9.04, trading between a resistance of $84.86 and support of $60.60. The analysis suggests a "Sell" signal based on a combination of indicators and moving averages, with 0 buy signals and 2 sell signals from indicators, and 4 buy and 2 sell signals from moving averages.
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Haemonetics Corp (HAE), detailing its regional revenue contributions. As of the latest update on April 6, the United States accounts for the majority of revenue at 73.08%, followed by Europe, Asia, and Japan. The company has not yet disclosed data concerning revenue contributions by business segment for the specified fiscal periods.
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Haemonetics Corp's (HAE) dividend and stock split history. It notes that no dividends have been distributed in the past five years and there is no data available for stock splits. The company's current stock price, market cap, and P/E TTM are also displayed.
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 Tells Investors
Haemonetics Corp (HAE) shares dropped 3.2% to $74.43, placing it 12.1% below its GF Value™ estimate of $84.68, suggesting it is modestly undervalued. The company holds a GF Score™ of 77/100, indicating above-average quality despite a low momentum rank and moderate financial strength. No insider transactions have occurred recently, implying a neutral stance from company insiders.
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Haemonetics Corp (HAE), highlighting its current earnings forecast score of 7.82, ranking 119 out of 204 in the Healthcare Equipment & Supplies industry. It details an average analyst price target of $88.00, with a consensus "Buy" rating based on 11 analysts. The report also includes expected revenue for the next quarter, historical and forecasted EPS, and peer comparisons.
HAE Maintained by Mizuho -- Price Target Raised to $85.00
Mizuho has maintained an "Outperform" rating for Haemonetics (HAE) and raised its price target from $70.00 to $85.00, indicating confidence in the company's growth. GuruFocus assesses HAE as 8.8% undervalued with a strong GF Score™ of 77/100, suggesting a potential buying opportunity for investors. Despite a moderate financial strength rating, the company shows strengths in profitability and valuation, although momentum is low.
Mizuho raises Haemonetics stock price target to $85 on plasma demand
Mizuho raised its price target for Haemonetics Corp. shares to $85 from $70, maintaining an Outperform rating due to strong performance in the company's plasma-collection business and healthy demand for intravenous immunoglobulin products. This comes after Haemonetics reported better-than-expected Q4 FY26 earnings and restructured its financial reporting segments, with BofA Securities also upgrading the stock to Buy. The analyst noted consistent investor interest in the stock's outperformance, driven by its NexSys system's superiority and robust core atrial fibrillation volumes.
HAE SEC Filings - Haemonetics Corp Mass 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Haemonetics Corporation's (HAE) SEC filings, including annual 10-K reports, quarterly 10-Q statements, 8-K material event disclosures, and insider trading forms. It details recent filings such as insider trading activities on July 25, 2025, and an executive stock sale on June 26, 2025, along with the company's financial data and rankings. StockTitan tracks 44 SEC filings for HAE, offering AI-generated summaries and sentiment analysis.
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices?
Haemonetics (HAE) is gaining investor attention due to increased interest in the medical device sector and internal restructuring, including merging its Plasma and Blood Center units into a single Apheresis segment. Despite analyst concerns about competition in vascular closure and the need for improved margins, the company's valuation appears modestly undervalued. This reorganization aims to provide clearer insights into management's performance in its core franchises, especially concerning profitability and market strategy.
[ARS] HAEMONETICS CORP SEC Filing
This article announces an ARS filing by Haemonetics Corp (HAE) on June 9, 2026, which is categorized with a low filing impact and neutral sentiment. The filing is available as a PDF document through SEC EDGAR. The page also provides an overview of HAE stock, including market capitalization, recent news, and other SEC filings, with links to the company's stock data and further information.
Haemonetics Jumps 6.6% Amid Sector-Wide Rally
Haemonetics Corporation (HAE) saw a significant 6.6% increase in its stock price, reaching $79.83, as part of a broader rally across the medical device sector. This surge, which also impacted other medical device companies, suggests a renewed investor interest in the industry rather than being driven by company-specific news for Haemonetics. The article notes that the coordinated sector strength indicates a potential re-evaluation of sector valuations or shifts in macroeconomic factors favoring device manufacturers.
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
Haemonetics (HAE) has restructured its business segments into Apheresis and MedSurg, with recent trading showing significant short-term share price returns. The stock is currently trading at $74.88, below an analyst target of $81.60, and is considered 13.8% undervalued with a fair value of $86.90 due to strong earnings quality, innovation in plasma collection, and new software contracts. Investors are encouraged to review company data and consider risks amid enthusiasm for its growth potential.
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares
Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp (NYSE: HAE), had 259 shares withheld at $71.28 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This tax-withholding disposition is a standard procedure and not an open-market sale. After this transaction, Ms. Maunsell Farris beneficially owns 6,242 common shares, which include previously reported unvested RSUs.
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations
Haemonetics Corp's Senior Vice President of Human Resources, Laurie A. Miller, reported a tax-related disposition of 313 shares. These shares, valued at $71.28 each, were withheld to cover tax obligations upon the vesting of previously granted restricted stock units. Following this transaction, Miller directly holds 40,987 shares, including unvested RSUs.
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology
Haemonetics Corp is a specialized medical technology company focused on blood and plasma management systems, attracting investor interest due to its strong market position in the US healthcare sector. The company's business model relies on devices, recurring consumables, and software solutions for hospitals and plasma centers, benefiting from stable demand driven by demographic trends and the critical nature of its products. This setup provides a measure of resilience against economic fluctuations and offers investors exposure to medical technology innovation and healthcare efficiency.
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately
This article analyzes Haemonetics (HAE) stock's recent performance and valuation using two approaches: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. While the DCF model suggests the stock is undervalued by 42.8%, the P/E ratio indicates it is somewhat overvalued compared to its fair ratio. The article also introduces "Narratives" as a way for investors to build their own fair value estimates based on different growth and risk assumptions for the company.
Haemonetics restructures reporting segments from three to two
Haemonetics Corporation is restructuring its financial reporting from three segments to two, combining Plasma and Blood Center into Apheresis and renaming Hospital to MedSurg. This change aims to better align external reporting with internal management, and the new structure will be used starting with the first quarter of fiscal year 2027. The company has also provided recast historical revenue data and confirmed its strong financial performance, including exceeding Q4 2026 earnings expectations and receiving an analyst upgrade.
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg
Haemonetics Corp is reorganizing its financial reporting into two main segments, Apheresis and MedSurg, starting in the first quarter of fiscal year 2027. This change aims to better align external reporting with the company's internal management and capital allocation strategies, moving from its previous three-segment structure. Haemonetics has provided recast historical financial data for fiscal years 2024-2026 to help investors compare performance under the new framework.
Medical tech firm Haemonetics merges plasma, blood segments into Apheresis
Haemonetics (NYSE: HAE) is updating its financial reporting segments, reducing them from three to two. The former Plasma and Blood Center segments will be combined into a new Apheresis segment, and the Hospital segment will be renamed MedSurg. This change, effective from Q1 fiscal 2027, aims to better align external reporting with the company's internal management and resource allocation.
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis
Haemonetics announced a reorganization of its reportable segments, consolidating Plasma and Blood Center into Apheresis and renaming Hospital to MedSurg. This transition from three to two segments aligns with their new management structure, with new reporting to begin in Q1 fiscal 2027. The company has also provided recast historical revenue data for comparability and re-issued fiscal 2027 revenue guidance under the new segments without reaffirming or updating it.
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments
Haemonetics (NYSE: HAE) announced a reorganization of its financial reporting structure, consolidating from three segments (Plasma, Blood Center, Hospital) into two: Apheresis and MedSurg. This change, effective with the first quarter of fiscal 2027 (starting March 29, 2026), aims to better align external reporting with internal management. The company has provided recast historical revenue data for fiscal years 2024-2026 and fiscal 2027 guidance under the new structure to aid comparability for investors.
Haemonetics Updates Financial Reporting Segments
Haemonetics Corporation announced an update to its financial reporting segments, transitioning from three to two. The Plasma and Blood Center segments will combine into an "Apheresis" segment, and the "Hospital" segment will be renamed "MedSurg." This change aims to better align external reporting with internal business management and resource allocation, with the new structure taking effect in the first quarter of fiscal year 2027.
HAE - Haemonetics Corp Stock Price and Quote
This article provides a comprehensive overview of Haemonetics Corp (HAE) stock, including its latest financials, key performance indicators, and recent news. It details analyst ratings and price targets, along with a historical log of upgrades and downgrades. The company's business segments and executive leadership are also outlined, accompanied by a recent insider transaction report.
Haemonetics earnings ahead: Can vascular closure rebound?
Haemonetics is set to report its fourth-quarter fiscal 2026 results, with analysts expecting a 7.6% increase in earnings per share and 2.0% revenue growth year-over-year. Investors will be keenly watching the performance of its vascular closure business following recent product approvals and acquisitions, particularly for signs that these developments are translating into new contracts and contributing to fiscal 2027 growth. The company's stock trades at a discount to its historical valuation, putting pressure on the upcoming report and guidance to justify Wall Street's bullish outlook.
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics Corporation (NYSE: HAE) announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 11, 2026. Chief Executive Officer, Stewart Strong, will deliver a presentation which will be accessible via webcast.
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics Corporation announced that its President and CEO, Chris Simon, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. A live webcast will be available on the company's Investor Relations website, with a replay accessible for 90 days after the event. Haemonetics is a global medical technology company focused on improving healthcare quality and efficiency.
Goldman Sachs healthcare forum hosts Haemonetics CEO fireside chat
Haemonetics (NYSE: HAE) announced its President and CEO, Chris Simon, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. A live webcast and 90-day replay of the event will be available on the company's Investor Relations website. This engagement is part of Haemonetics' continued investor outreach, following recent positive news regarding earnings and FDA approvals.
HAE Maintained by Citigroup -- Price Target Raised to $70
Citigroup has maintained its Neutral rating on Haemonetics (HAE) but raised the price target to $70 from $64, indicating cautious optimism for the company. Despite strong profitability and growth metrics, Haemonetics is considered undervalued by GuruFocus with a GF Value™ of $84.38 against its current trading price of $67.08. The company’s GF Score™ of 79/100, driven by solid financial strength, profitability, and growth, suggests a well-rounded performance, though momentum is currently low.
HAE News | HAEMONETICS CORP/MASS (NYSE:HAE)
This page provides recent news and analysis for Haemonetics Corporation (NYSE: HAE). It lists several articles from ChartMill and Zacks, covering topics such as quality tests, international revenue trends, options market predictions, and Q4 earnings performance. The article also displays the current stock price and trading information for HAE.
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings
Haemonetics' recent weak earnings might be due to conservative accounting practices, specifically the impact of US$90m in unusual items that reduced statutory profit. The article suggests that if these non-recurring expenses are excluded, the company's underlying profitability could be better than the reported figures, implying a potential increase in future profit. Investors are encouraged to look beyond headline numbers and consider these underlying factors when evaluating HAE.
